And, treatment strategies for localized prostate cancer linked to distinct pattern of adverse effects
TUESDAY, March 21, 2017 (HealthDay News) — For men with localized prostate cancer, radical prostatectomy is associated with a greater decrease in sexual domain scores, while different treatment strategies are associated with distinct patterns of adverse effects, according to two studies published in the March 21 issue of the Journal of the American Medical Association.
Daniel A. Barocas, M.D., M.P.H., from the Vanderbilt University Medical Center in Nashville, Tenn., and colleagues compared functional outcomes and adverse effects in 2,550 men diagnosed with clinical stage cT1 to 2 localized prostate cancer. Overall, 59.7, 23.5, and 16.8 percent underwent radical prostatectomy, external beam radiation therapy (EBRT), and active surveillance, respectively. The researchers found that the adjusted mean sexual domain score decreased more for radical prostatectomy than for EBRT at three years. Radical prostatectomy correlated with worse urinary incontinence than EBRT and active surveillance.
Ronald C. Chen, M.D., M.P.H., from the University of North Carolina at Chapel Hill, and colleagues compared quality of life among 1,141 men with newly diagnosed prostate cancer. Overall, 27.5, 41.1, 21.8, and 9.6 percent of men underwent active surveillance, radical prostatectomy, EBRT, and brachytherapy, respectively. The researchers found that, compared with active surveillance, the mean sexual dysfunction scores worsened by three months for patients who received radical prostatectomy, EBRT, and brachytherapy. Compared with active surveillance, worsened urinary incontinence was associated with radical prostatectomy; acute worsening of urinary obstruction and irritation were associated with EBRT and brachytherapy; and worsened bowel symptoms were associated with EBRT.
“These findings can be used to promote treatment decisions that incorporate individual preferences,” Chen and colleagues write.
Several authors from both studies disclosed financial ties to the biopharmaceutical industry.
Abstract/Full Text – Barocas (subscription or payment may be required)
Abstract/Full Text – Chen (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2017 HealthDay. All rights reserved.
